Letter to the Editor

Progressive Multifocal Leukoencephalopathy

Authors: Marco Cei, MD, Nicola Mumoli, MD, Giampiero Ferrito, MD, Fabio Scazzeri, MD

Abstract

To the Editor:


Progressive multifocal leukoencephalopathy (PML) is a progressive demyelinating disease of the central nervous system thought to be caused by the reactivation of JC papova virus that is becoming more prevalent than in the past with the increasing use of monoclonal antibodies for the treatment of neoplastic or autoimmune diseases. We report a case in which PML is the consequence of chronic lymphatic leukemia treated with a conventional approach.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816–824.
 
2. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007;17:72–74.
 
3. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538–1539.
 
4. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008;86:1474–1478.
 
5. Kuehn BM. Rare neurological condition linked to newer monoclonal antibody biologics. JAMA 2009;301:1423–1424.